如果是金属裸支架，我们维持双重抗血小板治疗几个月。
If it is a bare metal stent, we keep up the dual anti-platelet therapy for just a few months.
FDA也推荐介入治疗后至少延长一年对病人进行双重抗血小板治疗。
The FDA also recommends prolonged dual antiplatelet therapy for at least a year following the intervention.
最大的变化是抗血小板药物的使用率增加，比如双重抗血小板治疗以及抗凝治疗。
The biggest change has been in the increased use of international therapy and anti-platelet agents as dual anti-platelet therapy, and antithrombotics.
双重抗血小板治疗的最佳持续时间取决于特定心脏指征(见本增刊中其他篇目)。
The optimal duration of dual antiplatelet therapy depends on the specific cardiac indication (see other articles in this supplement) for recommended for specific indications.
第一年结束的时候，患者被随机分为继续双重抗血小板治疗组和停止抗凝治疗组。
At the end of one year, they are randomized to continue their dual anti-platelet therapy or having it stopped.
这就是我们需要的这种研究，目的是最终决定我们真正需要持续双重抗血小板治疗多长时间。
That is the kind of study that we need to have in order to make a final decision about how long we really need to continue dual anti-platelet therapy.
接受药物洗脱支架的患者长病变和复杂病变比接受裸金属支架的患者多，而且接受双重抗血小板治疗1年的可能性较大。
DES recipients had longer and more complex lesions than BMS recipients and also were more likely to be receiving dual antiplatelet therapy at 1 year.
目前，对于接受药物洗脱支架的患者，我们尝试维持双重抗血小板治疗在一年以上，因为我们非常关注晚期支架内血栓形成的可能性。
Right now, we try to keep dual anti-platelet therapy going for up to one year in patients who have a drug-eluting stent because we are very concerned about the possibility of late-stent thrombosis.
幸运的是，目前已经有一个试验正在进行，这就是DAPT研究，该研究观察了一个庞大的接受支架治疗及正在接受双重抗血小板治疗的患者群。
Fortunately, there is one ongoing right now. It is the DAPT Study, looking at a very large number of patients who have received a stent and are getting dual anti-platelet therapy.
尽管普遍认为抗凝疗法可预防静脉血栓形成，双重抗血小板疗法仍可用来治疗适应性较差的患者。
Although it is presumed that prevention of venous thrombosis is best achieved with anticoagulation, dual antiplatelet therapy can be a substitute for patients with poor compliance.
尽管普遍认为抗凝疗法可预防静脉血栓形成，双重抗血小板疗法仍可用来治疗适应性较差的患者。
Although it is presumed that prevention of venous thrombosis is best achieved with anticoagulation, dual antiplatelet therapy can be a substitute for patients with poor compliance.
应用推荐